Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Daniel Sinsimer,Jennie Zhang,Abderrahmane Laadem,Uwe Platzbecker,Alan F List,María Díez-Campelo,Peter G Linde,Carlo Finelli,Rodrigo Ito,Amer M Zeidan,Anita Rampersad,Pierre Fenaux,Valeria Santini,Rami S Komrokji,Ghulam J Mufti,Mario Cazzola,Amit Verma,Mikkael A Sekeres,Rena Buckstein,Guillermo Garcia‐Manero ,Osman İlhan

doi:10.1182/blood-2019-123064

Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Daniel Sinsimer, Jennie Zhang + Show 19 more

Open Access

https://doi.org/10.1182/blood-2019-123064

Copy DOI

#Require Red Blood Cell Transfusion #Research Funding + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Full Text